MedTrace Logo

Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices

NCT07268937 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-12-08

No results posted yet for this study

Summary

Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.

Methods for the quantitative and non-invasive assessment of liver fat content have recently been implemented on ultrasound devices, based on the estimation of the ultrasound beam attenuation coefficient and backscattering. These methods are CE marked and already commercially available.

The aim of the study is to compare the results of the degree of steatosis detected by different ultrasound devices with the degree of steatosis of the CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.

Conditions

  • Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

DEVICE

CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.

Use of the CAP module implemented on the Fibroscan machine to compare the results of the degree of steatosis

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2025-05-05
Completion
2025-05-05

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07268937 on ClinicalTrials.gov